SelectQuote Shares Fall 30% as 2027 Revenue Outlook Extends $1 Listing Shortfall
OVERLAND PARK, Kansas, August 25, 2026, 16:00 EDT — SelectQuote shares slumped 30% after the company projected lower-than-anticipated revenues for 2027, deepening its struggle to close the gap with the $1 minimum required for continued listing.
NYSE:SLQT · Post-close investor dashboard
SelectQuote: guide shock meets a listing gap
Market data: August 25, 2026, 16:00 EDT
Financials: quarter ended June 30, 2026
Financials: quarter ended June 30, 2026
Official close
$0.5402
▼ 30.39%
Range: $0.4854–$0.6750
Trading activity
9.46M
9.0× 20-day average
Regular-session volume
Quoted equity value
$94.0M
≈$41M erased
Derived from the 30.39% move
Distance to NYSE $1
+85.1%
Required to regain threshold
Current price equals 54.0% of $1
What reset the shares
Guide midpoint vs FY2026: $1.40B ÷ $1.60B − 1 = −12.5%
Guide midpoint vs consensus: $1.40B ÷ $1.74B − 1 = −19.5%
Guide midpoint vs consensus: $1.40B ÷ $1.74B − 1 = −19.5%
Quarter in four numbers
| Revenue | $321.7M | −7% |
| Revenue vs consensus | −$31.7M | −9.0% |
| Net result | −$16.8M | from +$12.9M |
| Adjusted EBITDA | $11.9M | from $2.7M |
Q4 fiscal 2026 versus Q4 fiscal 2025, except consensus comparison.
Operating signals
| Segment / metric | Q4 FY26 | YoY |
|---|---|---|
| Senior revenue | $72.5M | −12% |
| Approved MA policies | 72,180 | −15% |
| Healthcare Services revenue | $193.5M | −10% |
| SelectRx members | 109,039 | +1% |
| Prescriptions per day | 31,711 | +3.5% |
| Life adjusted EBITDA | $9.8M | +41% |
Fiscal 2027 bridge
| Management target | FY2027 | Signal |
|---|---|---|
| Revenue | $1.35B–$1.45B | −9% to −16% |
| Adjusted EBITDA | $90M–$115M | midpoint −6% |
| Operating cash flow | >$60M | about 2× |
| Free cash flow | ≈$50M | new target |
| Annual tech savings | >$30M | execution needed |
Analyst expectations
| Source | Rating | Target | Date |
|---|---|---|---|
| Craig-Hallum | Buy | $3.00 | Feb 6 |
| RBC | Hold | $5.00 | Nov 20 |
| Jefferies | Hold | $2.00 | Nov 10 |
| 4-analyst consensus | Buy | $3.06 | Aug 25 |
Consensus target upside: $3.06 ÷ $0.5402 − 1 = 466.5%
Wide dispersion and older targets reduce signal quality.
Wide dispersion and older targets reduce signal quality.
Capital structure watch
| Cash and restricted cash | $20.7M |
| Current + long-term debt | $370.2M |
| Preferred carrying value | $298.2M |
| Preferred liquidation preference | $423.2M |
| FY2026 operating cash flow | $31.9M |
Investor read-through
The market is valuing cash-flow execution over member growth. SelectRx prescriptions rose, but consolidated revenue contracted and the new guide sits well below consensus. The next proof points are delivery of more than $60 million in operating cash flow, realization of at least $30 million in savings, and a sustained recovery toward the NYSE's $1 minimum.
Sources: SelectQuote fiscal 2026 results and balance sheet; SelectQuote NYSE continued-listing notice; StockAnalysis closing data and consensus snapshot; Investing.com recommendation history. Prices and volume are regular-session data as of August 25, 2026, 16:00 EDT. Derived figures may differ slightly because of rounding.
TechStock² Updates
